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Background. The cytokine network remarkably inﬂuences homeostasis. There is not a complex analysis describing physiologi-
cal values of soluble cytokines in healthy individuals. Methods. Authors used the ELISA method to detect soluble cytokines and
costimulatory molecules simultaneously in the plasma of 30 blood donors. Results. Data are shown as (a range of concentrations;
median) IL-2 (0–74.48pg/mL; 0), IL-4 (0–65.18pg/mL; 0), IL-5 (0–86.69pg/mL; 0), IL-6 (0–73.17pg/mL; 0), IL-8 (0–74.8pg/mL;
0), IL-10 (0–12.6pg/mL; 0), IL-13 (0–3.9pg/mL; 0), sCD40L (0–3.5ng/mL;0),andTNF-α (0–67.6; 0). For the IL-6 receptor, the
concentration was 75.89 ± 35.83ng/mL (average ± SD), sCD23 28.9 ± 15.22ng/mL, and TGFβ11 4 .98 ± 12.39ng/mL. A special
approach was taken for the analysis of values, which had median 0. A model for the probability of detectable level’s occurrence for
each interleukin was formulated with intervals of conﬁdence. Conclusion. These results provide reference values for cytokine levels
in the plasma of healthy individuals.
Copyright © 2006 Klabusay Martin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Cytokines are biologically active macromolecules of protein
structure. They constitute a part of other signaling pathways
and their functions are fully developed after binding to spe-
ciﬁc receptors. Cytokines act pleiotropically, are redundant,
and act at minimal concentrations (ng/mL to pg/mL). They
regulate the expression of costimulatory and accessory mole-
cules on the cell surface. Today, the term “cytokines” also
includes other regulatory proteins, particularly monokines,
interleukins, interferons, and growth factors, which can
potentially be produced by every nuclear cell while their
pleiotropic eﬀects on various cells are maintained [1].
The cytokine receptors mostly bind cytokines with high
aﬃnity. They are expressed as inducible on the cell surface
and their expression increases after activation. It is not easy
to classify cytokines into groups because some molecules can
be aﬃliated into more than one category. One of the cur-
rent classiﬁcations divides cytokines on the basis of their
functions: cytokines that regulate hematopoiesis (SCF—
stem cell factor, FLT3—ligand, interleukin-3, CSF—colony-
stimulating factors: G-CSF, GM-CSF and M-CSF, erythro-
poetin, thrombopoetin); interferons (IFN-α,I F N - β,I F N - γ);
cytokines that mostly regulate the functions of B- and T-
lymphocyte systems (cytokines of the Th1 subset: IL-2, 3,
IFN-γ, and TNF, cytokines of the Th2 subset: IL-3, IL-4, IL-
5, IL-6, IL-10, and IL-13, cytokines produced by quench-
ing cytotoxic CD8+ T-lymphocytes and inductor helper T-
lymphocytes-Th3 subset: IL-10 and by transforming growth
factor β); pluripotent inﬂammatory cytokines (IL-1 and IL-
6); tumor necrosis factors; chemokines (according to the
original names IL-8, MIP-1-α, β, RANTES, MCP-1, TARC,
and others); and growth factors (TGFβ,P D G F — p l a t e l e t -
derived growth factor, FGF—ﬁbroblast growth factor,
VEGF—vascular endothelial growth factor, KGF—growth
factor for keratinocytes, and others) [1]. The discovery and2 Mediators of Inﬂammation
characterization of new cytokines are accompanied by the
identiﬁcation of genes similar to those of the previously de-
scribed cytokines.
Hematooncology is one ﬁeld in which the application of
some cytokines has already found its place as a standard part
of therapy: the use of recombinant hematopoietic growth
factors (G-CSF and GM-CSF) for the CD34+ cell compart-
ment mobilization, and the collection of PBSC (peripheral
blood stem cells) for the transplantation of hematopoiesis
and treatment of neutropenia [2, 3]. IL-2 and IFN-α are used
in treating solid tumors (kidney cancer), chronic myeloid
leukemia,andnon-Hodgkin’slymphoma.Anticytokinether-
apy by inﬂiximab (anti-TNF-α) is used in rheumatology
[1, 4, 5].
The cytokine concentration in body ﬂuid or tissue cul-
ture supernatants can be determined immunochemically
with monoclonal antibodies (using ELISA, FIA, lumines-
cent immunoanalysis, ﬂow cytometry) or polyclonal anti-
bodies, immunohistochemically, at the mRNA level, or by
bioanalysis. When looking for a work that would refer to
the physiological limits of cytokines, growth factors, or se-
lected molecules, one encounters a lack of comprehensive
information. In works describing various shifts in cytokine
proﬁle in both nononcological and oncological diagnoses or
in post-transplant complications, the control group samples
are analyzed, as well, but in the majority of cases the control
group is not represented suﬃciently; the cytokine concentra-
tion in vitro in cultured cell lines is preferred, or the work is
selectively focused on a particular cytokine. The aim of our
work is to provide an actual range of physiological values in a
purposelyselectedgroupofobjectivelyhealthyindividuals—
blood donors.
METHODS
Material
Thirty healthy donors, selected as whole blood donors in the
Transfusion Department and Blood Bank, were included in
the analysis (15 women and 15 men). The average age of the
donors was 34 (median: 30.5, men: 32, women: 29). In re-
gard to the distribution of blood groups, type 0 predomi-
nated (n = 13), followed by groups A (n = 5), A1 (n = 4),
B( n = 4), A1B (n = 3), and there was one AB donor. The
distribution of blood groups in the Rh system (D) correlated
with the prevalence in the population.
All blood donors signed statements of informed consent
before blood samples were taken, and experiments were ap-
proved by the Ethics Committee of the University Hospital,
Brno, Czech Republic.
Sampleprocessing
Samples were transported in test tubes with EDTA in an in-
sulated box to the laboratory and processed within 2 hours.
Plasma was obtained by centrifugation (10min, 250g) and
stored at −80◦C before the analysis.
ELISA(enzyme-linkedimmunosorbentassay)
Instant ELISA kits (Bender MedSystems GmBH, Austria)
were used. The kits contained the microtitration plate with
adsorbed conjugate of the mouse monoclonal antibody
against determined antigens and nonspeciﬁc horseradish
peroxidase. Every plate contained a doublet of seven stan-
dards for construction of the calibration curve and blank,
and the pH of the washing phosphate-buﬀered saline (PBS)
solution with 1% tween 20 was adjusted to 7.4. Atetramethyl
benzidine (TMB) solution served as the substrate for the re-
dox reaction. Activity of the enzyme was stopped by 1M
phosphoric acid and absorbance was measured at 450nm.
The laboratory software Kim32 (Schoeller Pharma, Czech
Republic) was used to evaluate the results.
Evaluation
Data were evaluated statistically with the R-language pro-
gram. A special approach was taken to evaluate the data
for interleukins with frequent zero-value occurrence. Cor-
relation among particular cytokines and costimulatory
molecules (IL-2–IL-13, TNF-α, sIL-6-R, sCD23, sCD40L,
and TGFβ1) were tested in a 12 × 12 matrix against one
another and the Spearman order correlation coeﬃcient was
calculated. Gender and blood groups of subjects were tested
with Kolmogorov-Smirnov nonparametric tests against the
cytokines and costimulatory molecules concentrations. Be-
causethesemethodstestonlytheeﬀectonisolatedcytokines,
logistic regression was used to model the eﬀect of indepen-
dent values of gender and blood group on combinations of
cytokines.
RESULTS
From the data distribution, it was clear that the problem of
zero values of interleukins could not be resolved by a stan-
dard statistical approach. A zero value was aﬃxed to con-
centrations beneath the detection limit of the analysis, which
means that values designated as zero in this case are not de-
tectableusingthe relevantanalysisbutcanin factbe positive.
The results were divided into two parts: concentrations
of interleukins in the donor plasma and TNF-α,T G F β1,
sIL-6R, sCD23, and sCD40L concentrations. The median of
interleukin concentration, as well as the majority of mea-
sured values, was 0 (see Figure 1). To deal with the prob-
lem of “zero” values, a nonstandard strategy was chosen for
evaluating the data. It was possible to calculate the probabil-
ity of positive occurrence in the general population for IL-
2 through IL-13 cytokine levels, including conﬁdence inter-
vals. Although there were very few positive values (and there
is an assumption that positive values will appear in a healthy
population to a small extent), it was possible to calculate the
probability of the positive value incidence in a healthy donor
from 30 observations, including the conﬁdence interval.
We describe the values which diﬀered signiﬁcantly from
the majority of the measured data (remote and extreme),
as noted in detail below. The summary of zero-value dataKlabusay Martin et al 3
Table 1: Probabilities of occurence of detectable level of particular interleukin in plasma of healthy blood donors. P is probability of nonzero
values occurence of interleukin and conﬁdence interval at 5% level, % of population shows proportion of blood donors with nondetectable
level of particular interleukin and conﬁdence interval at 5% level, and detection limit shows limit for detecting particular interleukin in
ELISA assay.
PP interval % of population % interval Detection limit
IL-2 .067 (.056;.147) 93.3% (85.3%;94.4%) 2.3pg/mL
IL-4 .100 (.073;.204) 90% (79.6%;92.7%) 0.66pg/mL
IL-5 .167 (.11;.147) 83.3% (69.4%;89%) 0.92pg/mL
IL-6 .067 (.056;.147) 93.3% (85.3%;94.4%) 0.92pg/mL
CXCL8 .167 (.11;.306) 83.3% (69.4%;89%) 7.26pg/mL
IL-10 .033 (.038;.147) 96.7% (91.6%;96.2%) 0.66pg/mL
IL-13 .100 (.073;.20) 90% (79.6%;92.7%) 0.99pg/mL
Table 2: Medians and ranges of measured values of cytokines and costimulatory molecules (except interleukins). Percentage of population
describes proportion of blood donors with nondetectable level of particular cytokine. Detection limit shows limit for detecting particular
cytokine in ELISA assay.
Median Range of values % of population Detection limit
TNF-α < 1.65 0 −67.6pg/mL 52% 1.65pg/mL
TGFβ1 10.81 4 .98 ±12.39ng/mL 3.5% 0.06ng/mL
sCD23 27.62 8 .9 ±15.22ng/mL 7% 3.3ng/mL
sCD40L < 0.062 0 −3.5ng/mL 71% 0.062ng/mL
sIL-6R 68.75 75.89 ±35.83ng/mL 0% 0.01ng/mL
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Figure 1: Plasma concentration of measured interleukins. The
graph (box-and-whiskers plot) shows the median and extreme val-
ues of measured concentrations of interleukins IL-2, IL-4, IL-5, IL-
6,IL-8,IL-10,andIL-13.Therewasnocorrelationamongmeasured
extreme values of diﬀerent interleukins. All median values of in-
terleukins were 0. For the detection limits of particular assays, see
Table 1.
probability for particular interleukins, including the conﬁ-
dence intervals and detection limits, is shown in Table 1.
For instance, the P = .067 with an interval (.056;.147) was
calculated for IL-2, so the level of IL-2 for 93.3% of the
population interval (85.3;94.4) will be below the detection
limit. Nonzero values of IL-2 will be detected only in 5.6%
to 14.7% of the population. The conﬁdence intervals were
constructed at the 5% level. The description is analogous for
other interleukins.
As there were more detected values, standard statistical
evaluation was possible for TNF-α,T G F β1, sIL-6R, sCD23,
and sCD40L parameters (see Table 2). A graphic presenta-
tion of the data, including the remote and extreme values,
is shown in Figures 2 and 3. For other characteristics of the
blood donors groups, see Table 3.
Interleukins(IL-2,IL-4,IL-5,IL-6,CXCL8,IL-10,IL-13)
A certain amount of interleukins in plasma was measured in
only a few donors. Medians were equal to 0. The measured
extreme values are shown in Figure 1. There were 2 posi-
tive donors (men of approximately the same age: 41 and 42
years) with regard to IL-2 (values 64.86 and 74.48pg/mL),
theformerwithdetectedlevelxofIL-5,sIL-6R,solubleCD23
and CD40L molecules, and TGFβ1 simultaneously, and the
latter with TNF-α,s I L - 6 R ,a n dT G F β1. The majority of val-
ueswerebelowthedetectionlimitoftheanalysis(DL),which
in this case was 2.3pg/mL.
The IL-4 above DL (0.66pg/mL) level was found in 2
men and 1 woman; sIL-6R, sCD23, TGFβ1w e r ed e t e c t e di n
the men simultaneously and additionally IL-13 in 1 woman.
Interleukin-5 above DL 1.45pg/mL was measured in 2
men and 2 women. The men had measurable amounts of
sCD40L, TGFβ1, sIL-6R, and sCD23 in plasma, while they
diﬀered in the presence of IL-2 versus IL-6 + CXCL8. In one
woman, IL-10 and sIL-6R were above DL.
Two men had IL-6 levels above DL 0.92pg/mL, and ad-
ditionally they were positive for sIL-6R, sCD23, and TGFβ1;4 Mediators of Inﬂammation
Table 3: Average values (with standard deviations) of other characteristics of blood donors.
Gender
No
Age (years)
(av ± SD)
Haemoglobin
(g/L) (av ± SD)
Leucocyte count
(×109/L) (av ± SD)
Blood pressure
(mm Hg) (av ± SD)
ALT (μkat/L)
(av ± SD)
Height/weight
(m, kg) (av ± SD)
Males 15 35 ±10 150.1 ±9.15 .5 ±0.8 139 ±14.7/81.1 ±11.20 .5 ±0.41 .76 ±0.1/81.9 ±11.6
Females 15 32 ±10 132 ±5.75 .9 ±1.3 122 ±13.4/76.8 ±7.60 .3 ±0.11 .67 ±0.1/67.0 ±11.5
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Figure 2: Plasma concentration of tumor necrosis factor-α (TNF-α) and transforming growth factor β1( T G F β1) in the healthy blood
donors (box-and-whiskers plot). See the caption in Figure 1.
oneofthesemenalsohadpositive IL-5,CXCL8,andsCD40L
levels.
DL for CXCL8 was 7.26pg/mL. Two men and 3 women
were above this limit. In all of them, sIL-6R, sCD23, and
TGFβ1 were also detected. In the women, TNF-α and CD40L
were detected, as was IL-13 in one man and IL-5, IL-6 and
CD40L in the second man.
DL was 0.66pg/mL for interleukin 10 and there was 1
positive woman (at the same time with a positive value for
IL-5 and sIL-6R).
IL-13 level above DL 0.99pg/mL was determined in 2
men and 1 woman. In all of these, IL-6R, sCD23, and TGFβ1
w e r ed e t e c t e d ;i n1m a nC X C L 8a n di n1w o m a nI L - 4w e r e
detected, as well.
Tumornecrosisfactor-α(TNF-α)
The median of the TNF-α levels was 0, with DL 1.65pg/mL.
There was a diﬀerence in the TNF-α median in men and
women (0 versus 26.2pg/mL). The range of measured values
is shown in Figure 2.
Transforminggrowthfactorβ1(T GFβ1)
The average level of TGFβ1 concentrations was 14.98, with
SD 12.39 and median 10.8ng/mL. The median was slightly
diﬀerent for men and for women. The DL of the analysis
was 0.06ng/mL. The range of measured values is shown in
Figure 2.
SolubleCD23andCD40Lmolecules
The range of levels for sCD23 (DL 3.3ng/mL)was28.9 ±
SD 15.22 with median 27.6ng/mL, and the median of val-
ues for sCD40L with DL 0.062ng/mL was 0 (see Figure 3).
The detected levels in some men and women were present
together with positive values for sIL-6R, sCD23, TGFβ1,
and in some cases together with IL-2, IL-5, IL-6, CXCL8, or
TNF-α.
Solublereceptorforinterleukin-6(sIL-6R)
For sIL-6R (DL 0.01ng/mL), the average levels were 75.89 ±
35.83 with median 68.75ng/mL. The range of measured val-
u e si ss h o w ni nFigure 3.
The data analysisincluded testing forcorrelations among
particular cytokines and co-stimulatory molecules (IL-2–IL-
13,TNF-α,sIL-6-R,sCD23,sCD40L,TGFβ1)againstonean-
other using a Spearman order correlation coeﬃcient. Thus
60testswereperformed,butnodirectdependencewasfound
among the values (no test showed a signiﬁcant nonzero cor-
relation for P = .05).
The other factors (gender and blood group, including Rh
factor) were tested with a Kolmogorov-Smirnov nonpara-
metric test against the cytokines and costimulatory molecule
concentrations. None of the 36 tests proved signiﬁcance at
the P = .05 level. Logistic regression models described in
the methodology section were used to simulate the eﬀects ofKlabusay Martin et al 5
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Figure 3: Plasma concentration of soluble CD23, sCD40L, and sIL-6R in the healthy blood donors (box-and-whiskers plot). See the caption
in Figure 1.
independent values (gender and blood group) on combina-
tions of cytokines. No signiﬁcant correlations were found in
these models either.
DISCUSSION
Cytokineconcentrationinbodyﬂuidsvariesnaturallywithin
a certain range inﬂuenced by extrinsic and intrinsic factors
and depending on age. Most interleukins, unlike their recep-
tors, are not detected in the body ﬂuids of healthy individ-
uals. Although concentrations of cytokines have been mea-
sured in the blood of healthy subjects, few reports analyze
systematicallymorethanonecytokineinahomogeneousco-
hort. We used an adequate number of healthy individuals for
detecting the physiologic levels of cytokines, knowing as well
other blood parameters. We also used a speciﬁc statistical ap-
proach to analyze the results, which, because of many zero-
data values, are scarcely assessable using standard statistical
methods.Inthetextbelow,wediscussreferencevalueswhich
were described in particular publications to detect cytokine
concentration in serum from the peripheral blood of healthy
individuals. There is evidence, however, that analyses of cy-
tokine concentration in human plasma instead of serum are
more precise, for example, [6].
Interleukin 2 is an example of a cytokine that has been
used in clinical oncology in the treatment of renal cell car-
cinoma and melanoma [7]. Its clinical beneﬁt has been
tested in many other indications [8, 9]. Measurable IL-2
concentrations in the majority of observed samples were not
detected.
IL-4 has been regarded as a control for inﬂammatory
mediators’ production (TNF-α,I L - 1 ,P G E 2) and its clinical6 Mediators of Inﬂammation
importance is related, for instance, to the graft versus host
disease (GvHD) after allogeneic transplantation of bone
marrow. Modiﬁcation of the donor T-lymphocyte reaction
can reduce the risk of relapse and donor cell engraftment
failure [10]. sIL-6R, sCD23, TGFβ1, and IL-13 were simul-
taneously found, as well, in values above detection limits
(DL). The functions of IL-5 are joined with the eosinophiles
and B-lymphocytes. The eﬀe c to ft h e r a p ya g a i n s tI L - 5o v e r -
production in hypereosinophilic syndrome and atopic reac-
tions with monoclonal antibody mepolizumab has been de-
scribed [11]. Together with IFN-γ,T N F - α, and IL-13, this
appears to be a signiﬁcant predictor of acute GvHD devel-
opment after allogeneic nonrelated donor stem cell trans-
plantation [12], while it should not be detected in healthy
individuals. However, 17% of the tested group of individ-
uals had measurable concentrations of IL-5 in plasma. IL-
6 signiﬁcantly modulates the expression of other cytokines
and aﬀects those cytokines that participate in tumor growth
control. Thomas et al determined an IL-6 concentration
of 6pg/mL in serum of 10 healthy controls, but no cor-
relation was found between the detected level and age or
gender [13]. With DL 0.7pg/mL, Wierzbowska et al stated
the range in serum level for 24 healthy controls at 0.5–
16.6pg/mL (median 5.35) [14]. Using an analysis with rel-
atively high DL (10pg/mL), Gause et al detected serum IL-
6 levels in only 2 of 20 healthy donors [15]. In other con-
trol groups, a median of IL-6 was 2.6pg/mL, with a range
of 2.03–4.7pg/mL, or was not detected exactly [16, 17].
Watanabe et al published the results of observations of
the relation between hematopoietic cell mobilization and
endogenous productions of CXCL8, MIP-1α,T N F - α,a n d
interferon-γ (IFN-γ) in 20 PBSC donors [18]. Only CXCL8
correlated with the CD34+ cells and CFU-GM (colony-
forming unit—granulocyte-macrophage) increase. Its aver-
age value before stimulation was 7.1pg/mL, and after stim-
ulation it increased by as much as 30 times. We discovered
production of this chemokine in plasma only in 17% of
blood donors.
The possible utility of cytokines including interleukin 10
and adhesive molecules as prognostic markers in B-CLL has
been conﬁrmed [19]. Lu et al showed that IL-10 is a growth
factor unrelated to IL-6 for human malignant plasmablastic
cells [20]. In this work, there is reference to nonpublished
results when IL-10 was not proven in blood even in a large
group of healthy individuals (n = 150).
Themultifunctional eﬀect of IL-13 interferes with the in-
duction of CD23 expression on B-lymphocytes and B-cell
proliferation and stimulates IgE and IgG4 secretion. It has
potential application in B-CLL or Hodgkin’s disease treat-
ment where IL-13 works as the apoptosis and tumor growth
modulator [21]. Another possible application is in allogeneic
hematopoietic stem cell transplantation, where the IL-13
level in the graft donors was the most signiﬁcant predictor of
development of GvHD in the transplant recipient [12]. Mea-
surable plasma concentrations were found in 10% of blood
donors.
It has been conﬁrmed that the mononuclear cells from
peripheral blood of healthy individuals produce an amount
of TNF-α 10 times greater than do cells of patients with CLL
[6]. In the control volunteers group, TNF-α was under the
detection limit. Fuhrmann-Benzakein et al measured values
beneath 13pg/mL in healthy controls during observation of
angiogenic cytokines in patients with solid tumors [22]. Our
controls had a median of values equal to 0, with a maximum
value approximately 5 times higher than in the paper men-
tioned.
TGBβ1 has its signiﬁcance in angiogenesis regulation.
Plasma concentrations of angiogenic cytokines (bFGF, HGF,
VEGF, TGFβ,a n dT N F - α) of 40 healthy volunteers served
as reference values in the above-mentioned paper. The me-
dian of values for TGFβ was 16ng/mL (range of values 3–40)
[22],higherthanthemedianofplasmaTGFβ1inourc ontr ol
group.
The importance of CD23 antigen has been proven not
only in nononcological diseases (diabetes mellitus, asthma),
but also as a prediction factor in hairy cell leukemia (HCL)
and B-CLL [23, 24]. An average concentration of 47ng/mL
(values in a range of 10–91ng/mL) (manual BenderMedSys-
temsInstantELISAforhsCD23,2005)wasdetectedinserum
of 8 donors, in agreement with our results. Soluble CD40
ligand is a costimulating molecule involved in growth reg-
ulation and T-cell dependent B-lymphocytes survival [25].
Its increased level was found in patients with B-cell lym-
phomas, as well as with other B-lymphocyte derived malig-
nancies. Healthy controls had detectable serum concentra-
tions, as well.
Concentration of receptor for IL-6 was increased in pa-
tients with various hematooncological diseases that were
submitted to IL-2/IFN-α2a immunotherapy after bone mar-
row transplantation or donor lymphocyte transfusion, then
decreased to normal levels, that is, values of 20 ± 3ng/mL
[26]. According to the available data, the concentration of
sIL-6R can reach values from 65 to more than 200ng/mL in
theserumofhealthyindividuals.Themedianofvaluesinour
g r o u po fd o n o r sw a s6 7 .75ng/mL.
The immunopotention and immunoregulation eﬀects of
cytokines are a subject of interest for extensive research. The
relations between cytokine levels and stages of various on-
cological and nononcological diseases are being observed, as
well as their signiﬁcance in response to appropriate therapy.
Nonparametric statistical tests and logistic regression
models were used to test for possible correlations among
measured data, including combination of cytokines. We
did not ﬁnd correlations between plasma levels of inter-
leukins, sIL-6R, sCD23, sCD40L, TNF-α,T G F β1, and gen-
der or among cytokines themselves. Nor was there corre-
lation between concentrations of the cytokines and blood
groupsorRhfactoroftheblooddonors.Otherroutinelyper-
formed laboratory tests (including white blood cells count,
hemoglobin concentration, hematocrit, level of transami-
nases) did not correspond with elevated plasma levels of de-
tected cytokines. Because concentration of cytokines is of-
ten below the measurable level in plasma of healthy subjects,
however,ourworkdescribesaspeciﬁcapproachforhandling
the problem of zero-values data. The probability of occur-
rence of positive value was calculated in the blood donorKlabusay Martin et al 7
group for each particular interleukin, which was measured
in blood plasma.
ACKNOWLEDGMENT
This work was supported by Grant IGA MZ CR NR8003-3/
2004.
REFERENCES
[1] Thomson AW, Lotze MT, eds. The Cytokine Handbook. 4th ed.
London, UK: Academic Press; 2003.
[2] Singhal S, Powles R, Treleaven J, Horton C, Mehta J. Long-
term safety of GM-CSF (molgramostim) administration af-
ter allogeneic bone marrow transplantation for hematologic
malignancies: ﬁve-year follow-up of a double-blind ran-
domized placebo-controlled study. Leukemia and Lymphoma.
1997;24(3-4):301–307.
[3] Chiang K-Y, Lamb L, Clark J, Worthington-White D, Rich
I, Henslee-Downey PJ. Assessment of G-CSF stimulated BM
hematopoietic stem cells in normal donors. Cytotherapy.
2002;4(1):55–63.
[4] Bewtra M, Lichtenstein GR. Inﬂiximab use in Crohn’s disease.
Expert Opinion on Biological Therapy. 2005;5(4):589–599.
[5] Etemad L, Yu EB, Wanke LA. Dose adjustment over time of
etanercept and inﬂiximab in patients with rheumatoid arthri-
tis. Managed Care Interface. 2005;18(4):21–27.
[6] Foa R, Massaia M, Cardona S, et al. Production of tumor
necrosisfactor-alphabyB-cellchroniclymphocyticleukemkia
cells: a possible regulatory role of TNF in the progression of
the disease. Blood. 1990;76(2):393–400.
[7] Eklund JW, Kuzel TM. Interleukin-2 in the reatment of renal
cell carcinoma and malignant melanoma. Cancer Treatment
and Research. 2005;126:263–287.
[ 8 ]H s uW ,L e s n i a kM S ,T y l e rB ,B r e mH .L o c a ld e l i v e r yo f
interleukin-2 and adriamycin is synergistic in the treatment
of experimental malignant glioma. Journal of Neuro-Oncology.
2005;74(2):135–140.
[9] Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli
F. Interleukin-2 for the treatment of advanced acute myel-
ogenous leukemia patients with limited disease: updated ex-
perience with 20 cases. Leukemia and Lymphoma. 1996;21(5-
6):429–435.
[10] Krenger W, Ferrara JLM. Dysregulation of cytokines dur-
ing graft-versus-host disease. Journal of Hematotherapy. 1996;
5(1):3–14.
[11] Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-
5 (mepolizumab) therapy for hypereosinophilic syndromes.
Journal of Allergy and Clinical Immunology. 2004;113(1):115–
119.
[12] Jordan WJ, Brookes PA, Szydlo RM, Goldman JM, Lechler RI,
Ritter MA. IL-13 production by donor T cells is prognostic
of acute graft-versus-host disease following unrelated donor
stem cell transplantation. Blood. 2004;103(2):717–724.
[13] Thomas X, Hirschauer C, Troncy J, et al. Serum interleukin-
6 levels in adult acute myelogenous leukemia: relationship
with disease characteristics and outcome. Leukemia and Lym-
phoma. 1997;24(3-4):291–300.
[14] Wierzbowska A, Urba´ nska-Ry´ s H, Robak T. Circulating IL-6-
type cytokines and sIL-6R in patients with multiple myeloma.
British Journal of Haematology. 1999;105(2):412–419.
[15] Gause A, Spickermann D, Klein S, Diehl V, Pfreundschuh
M. Elevation of circulating IL-6 in patients with acute non-
lymphocytic leukemia. European Journal of Haematology.
1994;53(3):178–180.
[16] Lai R, O’Brien S, Maushouri T, et al. Prognostic value of
plasma interleukin-6 levels in patients with chronic lympho-
cytic leukemia. Cancer. 2002;95(5):1071–1075.
[17] Herold M, Schmalzl F, Zwierzina H. Increased serum inter-
leukin 6 levels in patients with myelodysplastic syndromes.
Leukemia Research. 1992;16(6-7):585–588.
[18] Watanabe T, Kawano Y, Kanamaru S, et al. Endogenous
interleukin-8 (IL-8) surge in granulocyte colony-stimulating
factor-induced peripheral bloodstem cell mobilization. Blood.
1999;93(4):1157–1163.
[19] Kamper EF, Papaphilis AD, Angelopoulou MK, et al. Serum
levels of tetranectin, intercellular adhesion molecule-1 and
interleukin-10 in B-chronic lymphocytic leukemia. Clinical
Biochemistry. 1999;32(8):639–645.
[20] Lu ZY, Zhang XG, Rodriguez C, et al. Interleukin-10 is a pro-
liferation factor but not a diﬀerentiation factor for human
myeloma cells. Blood. 1995;85(9):2521–2527.
[21] Wynn TA. IL-13 eﬀector functions. Annual Review of Im-
munology. 2003;21:425–456.
[22] Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, et al. El-
evated levels of angiogenic cytokines in the plasma of cancer
patients. International Journal of Cancer. 2000;85(1):40–45.
[23] Sarmiento MA, Palacios MF, Scolnik MP, et al. Evolution of
chronic lymphocytic leukemia. Predictive value of immu-
nophenotype, sCD23 and morphology. Medicina. 2002;
62(4):305–312.
[24] Schwarzmeier JD, Shehata M, Hilgarth M, et al. The role of
soluble CD23 in distinguishing stable and progressive forms
ofB-chroniclymphocyticleukemia.LeukemiaandLymphoma.
2002;43(3):549–554.
[25] Clodi K, Asgary Z, Zhao S, et al. Coexpression of CD40
and CD40 ligand in B-cell lymphoma cells. British Journal of
Haematology. 1998;103(1):270–275.
[26] T or enA,N o vickD ,A ck erst einA,OrR,Sla vinS,N aglerA.Sol-
uble IL-6 receptors (sIL-6R) in hematological patients receiv-
ing immunotherapy with IL-2/IFN-α or donor lymphocytes
following bone marrow transplantation. Bone Marrow Trans-
plantation. 1996;18(4):721–724.